U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Palmar neurofibroma

MedGen UID:
870396
•Concept ID:
C4024841
•
Neoplastic Process
Synonym: Palmar neurofibromas
 
HPO: HP:0007576

Definition

A neurofibroma (benign peripheral nerve sheath tumor) localized in the palm of the hand. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPalmar neurofibroma

Conditions with this feature

Neurofibromatosis, type III, mixed central and peripheral
MedGen UID:
419422
•Concept ID:
C2931480
•
Disease or Syndrome
See: Condition Record
Neurofibromatosis, type III, mixed central and peripheral

Professional guidelines

PubMed

Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
Colombo N, Lorusso D, Monk BJ, Slomovitz B, Hasegawa K, Nogueira-Rodrigues A, Zale M, Okpara CE, Barresi G, McKenzie J, Makker V
Oncologist 2024 Jan 5;29(1):25-35. doi: 10.1093/oncolo/oyad201. PMID: 37523661Free PMC Article
Cabozantinib for the treatment of hepatocellular carcinoma.
Personeni N, Rimassa L, Pressiani T, Smiroldo V, Santoro A
Expert Rev Anticancer Ther 2019 Oct;19(10):847-855. Epub 2019 Oct 11 doi: 10.1080/14737140.2019.1674141. PMID: 31603008
Clinical features and management of superficial fibromatoses.
Kelenjian S, Mattjie RA, Franz R, Biedermann T, Brockow K
J Dtsch Dermatol Ges 2019 Apr;17(4):393-397. Epub 2019 Mar 13 doi: 10.1111/ddg.13808. PMID: 30865379

Recent clinical studies

Etiology

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group
Lancet 2023 Sep 30;402(10408):1133-1146. Epub 2023 Jul 24 doi: 10.1016/S0140-6736(23)00961-3. PMID: 37499670
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK
Lancet Oncol 2022 Jul;23(7):888-898. Epub 2022 Jun 7 doi: 10.1016/S1470-2045(22)00290-X. PMID: 35688173Free PMC Article
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B
Lancet Oncol 2022 Jan;23(1):77-90. Epub 2021 Dec 13 doi: 10.1016/S1470-2045(21)00604-5. PMID: 34914889
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL
Lancet 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PMID: 29433850
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group
N Engl J Med 2012 Nov 8;367(19):1783-91. Epub 2012 Oct 1 doi: 10.1056/NEJMoa1209124. PMID: 23020162Free PMC Article

Diagnosis

Dyschromatosis universalis hereditaria.
Murthy AB, Palaniappan V, Karthikeyan K, Anbarasan V
Int J Dermatol 2023 Oct;62(10):1218-1227. Epub 2023 Aug 27 doi: 10.1111/ijd.16817. PMID: 37634201
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group
Lancet Oncol 2021 Jul;22(7):977-990. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00252-7. PMID: 34143971
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werlé N, Saada E, Ray-Coquard I, Lervat C, Gaspar N, Marec-Berard P, Pacquement H, Wright J, Toulmonde M, Bessede A, Crombe A, Kind M, Bellera C, Blay JY
Lancet Oncol 2020 Mar;21(3):446-455. Epub 2020 Feb 17 doi: 10.1016/S1470-2045(19)30825-3. PMID: 32078813Free PMC Article
Acquired palmoplantar keratoderma.
Patel S, Zirwas M, English JC 3rd
Am J Clin Dermatol 2007;8(1):1-11. doi: 10.2165/00128071-200708010-00001. PMID: 17298101
Cowden syndrome.
Hanssen AM, Fryns JP
J Med Genet 1995 Feb;32(2):117-9. doi: 10.1136/jmg.32.2.117. PMID: 7760320Free PMC Article

Therapy

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group
Lancet 2023 Sep 30;402(10408):1133-1146. Epub 2023 Jul 24 doi: 10.1016/S0140-6736(23)00961-3. PMID: 37499670
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK
Lancet Oncol 2022 Jul;23(7):888-898. Epub 2022 Jun 7 doi: 10.1016/S1470-2045(22)00290-X. PMID: 35688173Free PMC Article
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B
Lancet Oncol 2022 Jan;23(1):77-90. Epub 2021 Dec 13 doi: 10.1016/S1470-2045(21)00604-5. PMID: 34914889
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL
Lancet 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PMID: 29433850
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group
N Engl J Med 2012 Nov 8;367(19):1783-91. Epub 2012 Oct 1 doi: 10.1056/NEJMoa1209124. PMID: 23020162Free PMC Article

Prognosis

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK
Lancet Oncol 2022 Jul;23(7):888-898. Epub 2022 Jun 7 doi: 10.1016/S1470-2045(22)00290-X. PMID: 35688173Free PMC Article
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group
Lancet Oncol 2021 Jul;22(7):977-990. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00252-7. PMID: 34143971
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL
Lancet 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PMID: 29433850
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators
Lancet Oncol 2016 Jul;17(7):917-927. Epub 2016 Jun 5 doi: 10.1016/S1470-2045(16)30107-3. PMID: 27279544
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group
N Engl J Med 2012 Nov 8;367(19):1783-91. Epub 2012 Oct 1 doi: 10.1056/NEJMoa1209124. PMID: 23020162Free PMC Article

Clinical prediction guides

The deep fascia and its role in chronic pain and pathological conditions: A review.
Kondrup F, Gaudreault N, Venne G
Clin Anat 2022 Jul;35(5):649-659. Epub 2022 Apr 27 doi: 10.1002/ca.23882. PMID: 35417568
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B
Lancet Oncol 2022 Jan;23(1):77-90. Epub 2021 Dec 13 doi: 10.1016/S1470-2045(21)00604-5. PMID: 34914889
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK
N Engl J Med 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002. PMID: 29972759Free PMC Article
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL
Lancet 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PMID: 29433850
Cabozantinib in progressive medullary thyroid cancer.
Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI
J Clin Oncol 2013 Oct 10;31(29):3639-46. Epub 2013 Sep 3 doi: 10.1200/JCO.2012.48.4659. PMID: 24002501Free PMC Article

Recent systematic reviews

Treatment of Dupuytren's contracture: a systematic review.
Soreide E, Murad MH, Denbeigh JM, Lewallen EA, Dudakovic A, Nordsletten L, van Wijnen AJ, Kakar S
Bone Joint J 2018 Sep;100-B(9):1138-1145. doi: 10.1302/0301-620X.100B9.BJJ-2017-1194.R2. PMID: 30168768
What do we know about managing Dupuytren's disease cost-effectively?
Dritsaki M, Rivero-Arias O, Gray A, Ball C, Nanchahal J
BMC Musculoskelet Disord 2018 Jan 25;19(1):34. doi: 10.1186/s12891-018-1949-2. PMID: 29370792Free PMC Article
Systematic review of non-surgical treatments for early dupuytren's disease.
Ball C, Izadi D, Verjee LS, Chan J, Nanchahal J
BMC Musculoskelet Disord 2016 Aug 15;17(1):345. doi: 10.1186/s12891-016-1200-y. PMID: 27526686Free PMC Article
Palmar fasciitis and polyarthritis syndrome-systematic literature review of 100 cases.
Manger B, Schett G
Semin Arthritis Rheum 2014 Aug;44(1):105-11. Epub 2014 Mar 6 doi: 10.1016/j.semarthrit.2014.03.005. PMID: 24684975
A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries.
Lanting R, Broekstra DC, Werker PMN, van den Heuvel ER
Plast Reconstr Surg 2014 Mar;133(3):593-603. doi: 10.1097/01.prs.0000438455.37604.0f. PMID: 24263394Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...